β-Catenin, a core component of Wnt/β-catenin signaling, has been shown to be a crucial factor in a broad range of tumors, while its role in glioma is not well understood. In this study, the expression of β-catenin in astrocytic glioma tissues with different grade and human normal cerebral tissues was examined using reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. We found a higher expression level of β-catenin in astrocytic glioma patients with high grade in comparison with the normal controls. Additionally, siRNA was transfected into human U251 glioblastoma cells by liposome after the design of siRNA was confirmed to effectively inhibit the expression of β-catenin by RT-PCR. Compared to the control siRNA group, siRNA-mediated knockdown of β-catenin in human U251 cells inhibited cell proliferation, resulted in cell apoptosis, and arrested cell cycle in G0/G1. Additionally, downregulation of β-catenin decreased the expression level of cyclin D1, c-Myc and c-jun. Taken together, these results indicate that overexpression of β-catenin may be an important contributing factor to glioma progression.
This is a preview of subscription content, log in to check access.
We are grateful to Prof. Qing Rao and Prof. Min Wang (Institute of Hematology and Blood Disease Hospital, China) for technical support. This work was supported by Postdoctoral Science Found (20080440423) of China and Clinical and Basic Cooperation Fund of Capital University of Medical Sciences (2006JL36).
Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science. 2000;287:1606–9.PubMedCrossRefGoogle Scholar
Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007;19:150–8.PubMedCrossRefGoogle Scholar
Dihlmann S, von Knebel Doeberitz M. Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer. 2005;113:515–24.PubMedCrossRefGoogle Scholar
Karim R, Tse G, Putti T, Scolyer R, Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology. 2004;36:120–8.PubMedCrossRefGoogle Scholar
Hatsell S, Rowlands T, Hiremath M, Cowin P. Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2003;8:145–58.PubMedCrossRefGoogle Scholar
Mann B, et al. Target genes of β-catenin-T cell-factor/lymphoidenhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA. 1999;96:1603–8.PubMedCrossRefGoogle Scholar
Rowlands TM, Pechenkina IV, Hatsell S, Cowin P. Beta-catenin and cyclin D1: connecting development to breast cancer. Cell Cycle. 2004;3:145–8.PubMedCrossRefGoogle Scholar
Pu P, et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther. 2009;16:351–61.PubMedCrossRefGoogle Scholar
Sareddy GR, Panigrahi M, Challa S, Mahadevan A, Babu PP. Activation of Wnt/beta-catenin/Tcf signaling pathway in human astrocytomas. Neurochem Int. 2009;55:307–17.PubMedCrossRefGoogle Scholar
Liu X, et al. Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis. Leukemia. 2009;23:739–45.PubMedCrossRefGoogle Scholar
Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using a small interference RNAs. Methods. 2002;26:199–213.PubMedCrossRefGoogle Scholar
Müller T, Choidas A, Reichmann E, Ullrich A. Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration. J Biol Chem. 1999;274:10173–83.PubMedCrossRefGoogle Scholar
Utsuki S, et al. Relationship between the expression of E-, N-cadherins and beta-catenin and tumor grade in astrocytomas. J Neurooncol. 2002;57:187–92.PubMedCrossRefGoogle Scholar
Sareddy GR, Challa S, Panigrahi M, Babu PP. Wnt/beta-catenin/Tcf signaling pathway activation in malignant progression of rat gliomas induced by transplacental N-ethyl-N-nitrosourea exposure. Neurochem Res. 2009;34:1278–88.PubMedCrossRefGoogle Scholar
1.Cerebrovascular Diseases Research Institute, Key Laboratory of Neurodegenerative Diseases of Ministry of Education and Department of Neurosurgery, Xuanwu HospitalCapital Medical UniversityBeijingPeople’s Republic of China
2.Department of Neurosurgery, Beijing Tiantan HospitalCapital University of Medical SciencesBeijingPeople’s Republic of China
3.Department of Neurosurgery, Beijing Tongren HospitalCapital University of Medical SciencesBeijingPeople’s Republic of China